{'fraction_non_alphanumeric': 0.0377787892580792, 'fraction_numerical': 0.04779244424214838, 'mean_word_length': 4.123543123543124, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Testing of Supramolecular Albendazole Effect on Somatic Larvae of Toxocara сanis in Laboratory Mice

The purpose of the research is to compare the effectiveness of the supramolecular complex of albendazole with basic albendazole at toxocarosis in laboratory mice to evaluate the potential prospects of a new drug in treatment of tissue Toxocara sp. infection. Materials and methods. The study used 75 female BALB/c mice. All mice were infected with infective Toxocara canis eggs by oral gavage once, by 800 infective eggs each. The mice in the test groups were given base albendazole (ABZ) and improved albendazole (ABZ-DDS) in a doses of 50 to 200 mg/kg. The mice in the control group were given distilled water of 50 mcl within the same time limits. T. canis eggs were cultivated to rear their infective stages in Petri dishes in a thermostat at 25 °С. ABZ and ABZ-DDS suspensions were prepared using distilled water and Tween-20 in proportions required to obtain necessary concentrations. The drug was given to mice by oral gavage in the amount of 0.2 to 0.5 ml per mouse. In order to separate and count Toxocara sp. larvae, the muscular tissue was minced and digested in the simulated gastric fluid (SGF) for 50 minutes in a ‘Gastros’ apparatus at 37 °С. The visceras, namely, liver, lungs, heart, kidneys and brain were minced and placed on a sieve into the SGF solution for 4 hours at 37 °С. The microscopy and counting of larvae were carried out using a microscope. Results and discussion. As of the 20th day after the infecting, the ABZ and ABZ-DDS efficacy was 59.25 and 65.82%; 66.95 and 69.70%; and 69.35 and 76.48% in a doses of 50, 100 and 200 mg/kg respectively. As of the 40th day after the infecting, the ABZ and ABZ-DDS efficacy was 66.54 and 70.87%; 68.03 and 73.41%; and 74.45 and 75.88% in a doses of 50, 100 and 200 mg/kg respectively. The number of T. canis larvae reduced in the mouse brain when the ABZ-DDS was applied in a doses of 100 and 200 mg/kg. There were not significant differences in the results of the therapy in different periods after the infecting (on the 20th and 40th day). As the dose was increased, the ABZ and ABZ-DDS efficacy was enhanced significantly.